

North Central Cancer Treatment Group

N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR<sup>®</sup> Depot) for Symptomatic Ascites in Cancer Patients

Status Change – July 13, 2007

**NOTICE OF STATUS CHANGE**

This study will re-open to patient accrual effective Friday, July 13, 2007.

IRB Approval of Addendum 2 is required prior to enrolling patients on this study.

**Please retain this notice with the protocol.**